Partner Headlines - EXEL

  1. Morning Market Gainers

    Benzinga
  2. Benzinga's Top #PreMarket Gainers

    Benzinga
  3. Benzinga's Top #PreMarket Gainers

    Benzinga
  4. Exelixis Prices 25M Share Offering @$5.40/Share

    Benzinga
  5. Benzinga's Top #PreMarket Losers

    Benzinga
  6. Ethical-Drug Firms Horizon Pharma, Bristol-Myers Rally

    IBD
  7. Bristol-Myers: kidney drug win

    IBD
  8. Market Update: Monday's Mid-Day Movers; Greece Opens Banks; Gold ...

    Benzinga
  9. Bristol-Myers, Exelixis Drugs Score Vs. Kidney Cancer

    IBD
  10. Mid-Morning Market Update: Markets Mostly Flat; Morgan Stanley ...

    Benzinga
  11. Benzinga's Top #PreMarket Gainers

    Benzinga
  12. Exelixis Announces Start of Phase 1 Trial of Cabozantinib in ...

    Benzinga
  13. Benzinga's Top #PreMarket Losers

    Benzinga
  14. Watch These 10 Stocks Over The Weekend

    Benzinga
  15. Morning Market Gainers

    Benzinga
  16. Benzinga's Top #PreMarket Gainers

    Benzinga
  17. Morning Market Gainers

    Benzinga
  18. Benzinga's Top #PreMarket Gainers

    Benzinga
  19. Exelixis Data Release Upcoming; Options Activity Spiking

    Benzinga
  20. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  21. 5-year lows: Synta Pharmaceuticals Inc, Exelixis Inc, Entropic ...

    GuruFocus
  22. Mid-Day Market Update: ON Semiconductor Surges On $1 Billion ...

    Benzinga
  23. Mid-Morning Market Update: Markets Open Lower; Weatherford To ...

    Benzinga
  24. Morning Market Losers

    Benzinga
  25. Events for the Week of Nov. 17-21, 2014

    Benzinga
  26. Morning Market Movers

    Benzinga
  27. 5-year lows: National Presto Industries, Ennis Inc, Landauer ...

    GuruFocus
  28. Stocks Hitting 52-Week Lows

    Benzinga
  29. Equities, Commodities & Bonds Finish Lower On First Trading Day ...

    Benzinga
  30. Midday Losers From Tuesday, September 2

    Benzinga
  31. Exelixis Shares Slide On Trial Results; Norwegian Cruise Line ...

    Benzinga
  32. Markets Mixed; Conn's Profit Misses Estimates

    Benzinga
  33. Stocks Hitting 52-Week Lows

    Benzinga
  34. Morning Market Losers

    Benzinga
  35. Benzinga's Top Downgrades

    Benzinga
  36. Stifel Nicolaus Downgrades Exelixis To Hold

    Benzinga
  37. Stocks To Watch For September 2, 2014

    Benzinga
  38. Exelixis Announces Results From COMET-1 Phase 3 Pivotal Trial ...

    Benzinga
  39. Mid-Afternoon Market Update: Harmonic Drops On Weak Forecast; ...

    Benzinga
  40. Harmonic Drops On Weak Forecast; URS Shares Surge

    Benzinga
  41. Mid-Morning Market Update: Markets Open Higher; Citigroup Profit ...

    Benzinga
  42. Morning Market Movers

    Benzinga
  43. Exelixis Shares Move 12% On Phase 3 Data

    Benzinga
  44. Benzinga's Top #PreMarket Gainers

    Benzinga
  45. Conferences/Events Scheduled for Week of Jun. 9th to Jun. 13th

    Benzinga
  46. Benzinga's Top #PreMarket Gainers

    Benzinga
  47. Five-Year Lows: Rentech Nitrogen Partners LP, SandRidge Permian ...

    GuruFocus
  48. Market Wrap For March 26: Markets Close Near Session Lows In ...

    Benzinga
  49. Mid-Afternoon Market Update: Markets Turn Red as Dish Network ...

    Benzinga
  50. Mid-Day Market Update: Five Below Jumps On Upbeat Results; Exelixis ...

    Benzinga
  51. Mid-Morning Market Update: Markets Open Higher; Francesca's Issues ...

    Benzinga
  52. Stocks Hitting 52-Week Lows

    Benzinga
  53. Morning Market Losers

    Benzinga
  54. Benzinga's Top #PreMarket Losers

    Benzinga
  55. Morning Market Movers

    Benzinga
  56. US Stock Futures Rise Ahead Of Housing Data

    Benzinga
  57. Exelixis Prices 10M Share Offering at $8 per Share

    Benzinga
  58. Oversold ETFs Looking Attractive (IHE, CSD, PSCE)

    Benzinga
  59. Exelixis Announces Promising Phase 1b Data for Cobimetinib in ...

    Benzinga
  60. US Stock Futures Rise Ahead Of Jobless Claims, GDP Data

    Benzinga
  61. Exelixis Announces Full Patient Enrollment for COMET-1 Phase ...

    Benzinga
  62. US Stock Futures Up After Upbeat China Data

    Benzinga
  63. Exelixis Initiates Phase 3 Clinical Trial of Cabozantinib

    Benzinga
  64. Exelixis Receives EMA Acceptance of Marketing Authorization App ...

    Benzinga
  65. Exelixis Inc. Reports Operating Results (10-Q)

    GuruFocus
  66. Exel Presents Interim Data for Cabozantinib 40 mg Dose Cohort ...

    Benzinga
  67. First Solar, Sears Holdings Among Stocks Down on Above-average ...

    FoxBusiness
  68. Exelixis Says FDA Says NDA Has Been Removed from November Agenda

    Benzinga
  69. UPDATE: Piper Jaffray Reduces PT to $4.50 on Exelixis on Equity ...

    Benzinga
  70. Social Media Outlook for Thursday August 9 (EAT, NOV, NWSA, FSYS)

    Benzinga
  71. Exelixis, Universal Display Corporation Among Stocks Up on High ...

    FoxBusiness
  72. FDA's Oncologic Drugs Advisory Committee to Review Exelixis New ...

    Benzinga
  73. Exelixis (EXEL) Loses 8.8% As Company Sells Stock, Debt

    MarketIntelligenceCenter
  74. Health Care Sector Wrap

    FoxBusiness
  75. HCA Holdings, American Capital Mortgage Investment Crp Among ...

    FoxBusiness
  76. Interpublic Group, Exelixis Gapping Down Monday

    FoxBusiness
  77. UPDATE: Exelixis Announces Proposed Convertible Debt Offering ...

    Benzinga
  78. Exelixis Proposed Offering 20M Shares

    Benzinga
  79. Exelixis Inc. Reports Operating Results (10-Q)

    GuruFocus
  80. Social Media Outlook for Monday July 30 (SHAW, BBY, EXEL, VHC)

    Benzinga
  81. Benzinga's Top Pre-Market Gainers

    Benzinga
  82. FDA Grants Priority Review for Cabozantinib in Medullary Thyroid ...

    Benzinga
  83. Exelixis Announces Initiation of Cabozantinib Investigator-Sponsored ...

    Benzinga
  84. Jefferies Reiterates Hold Rating, $6 PT for Exelixis

    Benzinga
  85. Cabozantinib Demonstrates Durable Effects in Bone and Soft Tissue ...

    Benzinga
  86. Cabozantinib Meets Primary Endpoint of Progression Free Survival ...

    Benzinga
  87. Cabozantinib Demonstrates Evidence of Anti-Tumor Effects in Heavily ...

    Benzinga
  88. Exelixis Completes Submission of New Drug Application for Cabozantinib ...

    Benzinga
  89. Exelixis Initiates COMET-1 Pivotal Trial Focused on Overall Survival ...

    Benzinga
  90. Exelixis Expands the Cabozantinib Development Program Through ...

    Benzinga
  91. Exelixis Announces Initiation of Investigator-Sponsored Clinical ...

    Benzinga
  92. 5 Resilient Biotech Stocks to Buy for 2012

    GuruFocus
  93. Top 4 NASDAQ Stocks In The Biotechnology Industry With The Lowest ...

    Benzinga
  94. Exelixis (EXEL) Gains 2.8% After Pricing 11 Million Share Offering ...

    MarketIntelligenceCenter
  95. Exelixis Announces Pricing of $60.5 Million Public Offering at ...

    Benzinga
  96. Exelixis Announces Proposed Public Offering of 10M Shares

    Benzinga
  97. Exelixis Reports Positive Preliminary Phase 2 Cabozantinib Data ...

    Benzinga
  98. Notable Call Options Activity on Exelixis

    Benzinga
  99. Exelixis Trading Higher After Licensing Agreement with Merck

    Benzinga
  100. Exelixis Lures Premium Sellers on Positive Drug Data

    SchaeffersResearch
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!